Home > Publications database > Quality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany. > print

001     304583
005     20250916115009.0
024 7 _ |a 10.1002/ijc.70152
|2 doi
024 7 _ |a pmid:40938250
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
037 _ _ |a DKFZ-2025-01906
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fabian, Alexander
|0 0000-0003-2415-527X
|b 0
245 _ _ |a Quality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany.
260 _ _ |a Bognor Regis
|c 2025
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1757942298_18238
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Germany has one of the highest cancer incidence rates in Europe. Radiotherapy is essential for patients with cancer as 50% have an evidence-based indication for radiotherapy. However, it is unknown how health-related quality of life (HRQoL) of cancer patients undergoing radiotherapy compares to the general population in Germany. Therefore, we conducted a secondary analysis by pooling cross-sectional individual-level data from a multicenter cohort of cancer patients (n = 1052) undergoing radiotherapy across Germany and a normative sample from the German general population (n = 1006). We used the EORTC QLQ-C30 to measure global HRQoL (range: 0-100). Higher scores indicate higher HRQoL. We used ANOVA for univariable and ANCOVA with predefined covariates for multivariable analyses. As per univariable analysis, cancer patients had significantly lower global HRQoL compared with the general population (mean [M] = 54.6 vs. M = 65.9; p < .001). This difference was smaller but persisted in the multivariable analysis (M = 56.5 vs. M = 63.5; p < .001). Multivariable analyses stratified by education showed that HRQoL was only lower in cancer patients with medium (M = 56.2 vs. M = 63.0; p < .001) or high education (M = 57.0 vs. M = 66.5; p < .001) compared with the general population. The minimal important difference threshold of seven points was only met in the group with high education. In conclusion, there may be a meaningful gap in HRQoL of cancer patients at the end of radiotherapy compared with the general population, mainly in patients with higher educational levels. Upon validation, this would highlight the need for supportive care and optimized radiotherapy strategies to eventually close the HRQoL gap.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a general population
|2 Other
650 _ 7 |a neoplasms
|2 Other
650 _ 7 |a quality of life
|2 Other
650 _ 7 |a radiotherapy
|2 Other
700 1 _ |a Rühle, Alexander
|b 1
700 1 _ |a Liegl, Gregor
|b 2
700 1 _ |a Domschikowski, Justus
|b 3
700 1 _ |a Trommer, Maike
|b 4
700 1 _ |a Ferdinandus, Simone
|b 5
700 1 _ |a Becker, Jan-Niklas
|b 6
700 1 _ |a Wurschi, Georg
|b 7
700 1 _ |a Boeke, Simon
|b 8
700 1 _ |a Sonnhoff, Mathias
|b 9
700 1 _ |a Grott, Christoph
|b 10
700 1 _ |a Käsmann, Lukas
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Schneider, Melanie
|b 12
700 1 _ |a Freitag-Wolf, Sandra
|b 13
700 1 _ |a Nicolay, Nils H
|b 14
700 1 _ |a Krug, David
|b 15
700 1 _ |a Nolte, Sandra
|0 0000-0001-6185-9423
|b 16
773 _ _ |a 10.1002/ijc.70152
|g p. ijc.70152
|0 PERI:(DE-600)1474822-8
|p nn
|t International journal of cancer
|v nn
|y 2025
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:304583
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2024-12-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2024-12-17
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21